# US 2013/0295050 A1 · Anti-igf-i receptor antibodies, dnas, vectors, host cells and genetic constructs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0295050 A1
- Document ID: US20130295050A1
- Status: Published application
- Kind: A1
- Application number: 13/616,832
- Filed: 2012-09-14
- Published: 2013-11-07
- Earliest claimed: 2002-06-14
- Assignees: ImmunoGen, Inc.
- Inventors: Rajeeva SINGH; Daniel J. TAVARES; Nancy E. DAGDIGIAN
- Web page: https://patentgrep.com/patent/US20130295050A1

## CPC

- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4745: condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines (yohimbine derivatives, vinblastine A61K31/475; ergoline derivatives A61K31/48)
- A61K 39/39541: {against normal tissues, cells}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

DNAs, vectors, host cells and genetic constructs of antibodies, humanized antibodies, resurfaced antibodies, antibody fragments, derivatized antibodies, and conjugates of these molecules with cytotoxic agents, which specifically bind to and inhibit insulin-like growth factor-I receptor, antagonize the effects of IGF-I and are substantially devoid of agonist activity toward the insulin-like growth factor-I receptor. These molecules can be conjugated to cytotoxic agents for use in the treatment of tumors that express elevated levels of IGF-I receptor, such as breast cancer, colon cancer, lung cancer, ovarian carcinoma, synovial sarcoma and pancreatic cancer. These molecules can also be labeled for in vitro and in vivo diagnostic uses, such as in the diagnosis and imaging of tumors that express elevated levels of IGF-I receptor.

## Claims

### Claim 1

A method for treating a cancer in a subject in need thereof, comprising:
administering to the subject an anti-IGFI-R antibody or fragment thereof that specifically binds to IGF-IR, wherein said antibody or fragment thereof comprises:
(a) at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein said heavy chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 1, a CDR2 having the amino acid sequence of either SEQ ID NO:2 or SEQ ID NO:54 and a CDR3 having the amino acid sequence of SEQ ID NO:3, and wherein said light chain variable region comprises a CDR1 having the amino acid sequence of SEQ ID NO: 4, a CDR2 having the amino acid sequence of SEQ ID NO:5 and a CDR3 having the amino acid sequence of SEQ ID NO:6, or
(b) at least one heavy chain variable region (VH) and at least one light chain variable region (VL), wherein said heavy chain variable region comprises a CDR1, CDR2 and CDR3 of the antibody produced by mouse hybridoma EM164 (ATCC accession number PTA 4457) and said light chain variable region comprises a CDR1, CDR2 and CDR3 of the antibody produced by mouse hybridoma EM164 (ATCC accession number PTA 4457); and
administering an additional therapeutic agent.

### Claim 2 (depends on 1)

The method of claim 1, wherein the framework of the VH region of the anti-IGFI-R antibody is at least 85% or more identical to the framework of the VH region of SEQ ID NO: 13; and wherein the framework of the VL region of the humanized anti-IGFI-R antibody is at least 85% or more identical to the framework of the VL region of SEQ ID NO: 9, 10, 11 or 12.

### Claim 3 (depends on 2)

The method of claim 2, wherein the framework of the VH region of the anti-IGFR-I antibody is at least 95% or more identical to the framework of the VH region of SEQ ID NO: 13 and wherein the framework of the VL region of the humanized anti-IGFI-R antibody is at least 95% or more identical to the framework of the VL region of SEQ ID NO: 9, 10, 11 or 12.

### Claim 4 (depends on 1)

The method of claim 1, wherein said antibody, or fragment thereof, is a human antibody, a humanized antibody, a resurfaced antibody, a chimeric antibody or an antibody produced by mouse hybridoma EM164 (ATCC accession number PTA 4457).

### Claim 5 (depends on 1)

The method of claim 1, wherein said antibody fragment is a Fab, Fab′2, ScFv, Fd or dAb.

### Claim 6 (depends on 1)

The method claim 1, wherein the isotype of the anti-IGFI-R is IgG, IgM, IgA, IgD or IgE.

### Claim 7 (depends on 1)

The method of claim 1, wherein said additional therapeutic agent is selected from the group consisting of docetaxel, paclitaxel, doxorubicin, epirubicin, cyclophosphamide, trastuzumab, capecitabine, tamoxifen, toremifene, letrozole, anastrozole, fulvestrant, exemestane, goserelin, oxaliplatin, carboplatin, cisplatin, dexamethasone, antide, bevacizumab, 5-fluorouracil, leucovorin, levamisole, irinotecan, etoposide, topotecan, gemcitabine, vinorelbine, estramustine, mitoxantrone, abarelix, zoledronate, streptozocin, rituximab, idarubicin, busulfan, chlorambucil, fludarabine, imatinib, cytarabine, ibritumomab, tositumomab, interferon alpha-2b, melphalam, bortezomib, altretamine, asparaginase, gefitinib, erlonitib, anti-EGF receptor (EGFR) antibody, interferon alpha-2a, vincristine, pamidronate, thalidomide, carmustine, prednisone, erythropoietin, bisphosphonate, antibody conjugate and an epothilone.

### Claim 8 (depends on 7)

The method of claim 7, wherein said additional therapeutic agent is an antibody conjugate comprising an anti-EGFR antibody or fragment thereof, wherein said fragment specifically binds to EGFR.

### Claim 9 (depends on 7)

The method of claim 7, wherein said additional therapeutic agent is selected from the group consisting of carboplatin, oxaliplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, camptothecin and an anti-EGFR antibody.

### Claim 10 (depends on 7)

The method of claim 7, wherein said additional therapeutic agent is selected from the group consisting of bortezomib, melphalan, thalidomide, doxorubicin, cyclophosphamide, interferon alpha-2b, interferon alpha-2a, vincristine, pamidronate, carmustine, zoledronate, and dexamethasone.

### Claim 11 (depends on 1)

The method of claim 1, wherein said antibody or fragment thereof is present in a composition, and wherein said composition optionally comprises a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

The method of claim 1, wherein said antibody or fragment thereof is a conjugate.

### Claim 13 (depends on 1)

The method of claim 1, wherein said antibody or fragment thereof is linked to a cytotoxic agent.

### Claim 14 (depends on 13)

The method of claim 13, wherein said cytotoxic agent is selected from the group consisting of a maytansinoid, a small drug, a prodrug, a taxoid, CC-1065 and a CC-1065 analog.

### Claim 15 (depends on 1)

The method of claim 1, wherein said cancer is a cancer selected from the group consisting of breast cancer, colon cancer, ovarian carcinoma, osteosarcoma, cervical cancer, prostate cancer, lung cancer, synovial carcinoma, pancreatic cancer, melanoma, multiple myeloma, neuroblastoma, and rhabdomyosarcoma.

### Claim 16 (depends on 1)

The method of claim 1, wherein said additional therapeutic agent is a cytotoxic agent.

### Claim 17 (depends on 13)

The method of claim 13, wherein said administering of said conjugate and said additional therapeutic agent is concurrently or sequentially and in either order.

### Claim 18 (depends on 1)

The method of claim 1, wherein the antibody, or fragment thereof, is administered intravenously, intramuscularly, or subcutaneously to the subject.

### Claim 19 (depends on 1)

The method of claim 1, wherein the antibody, or fragment thereof, is administered in combination with the additional therapeutic agent.
